Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose range finding and open-label extension study of branaplam in early manifest Huntington's disease
2020-000105-92Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing branaplam with placebo (2 arms). Primary endpoint: Pre-USM primary endpoints. Started Aug 2021; status: completed.
02
Drugs
branaplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2020-000105-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000105-92.